Company / Accounts Receivable
Integra Lifesciences Holdings Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$278.8M
FY2025
5-year range
$231.8M / $278.8M
FY2021-FY2025
Trend
+2.4%
vs FY2024
Sector context
#61 of 138
Health Care
What the data says
At $279M, Integra Lifesciences Holdings's accounts receivable ranks #61 of 138 in the Health Care sector. Accounts Receivable has fluctuated over the past 10 years, ranging from $148M in FY2016 to $279M in FY2025.
Based on SEC 10-K filings.
$279M in FY2025 with a 5-year CAGR of +4.3%.
Improved from $259M to $279M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +1.9%
- 5-Year CAGR
- +4.3%
- 10-Year CAGR
- -
Sector benchmark
#61 of 138 in Health CareTop 44% of 138This company $278.8M Sector average $1.3B
▼
-78.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.3%, indicating consistent growth.
- In FY2025, accounts receivable increased 2.4% year-over-year.
- Ranks #61 out of 138 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $278.8M | +2.4% |
| FY2024 | $272.4M | +5.0% |
| FY2023 | $259.3M | -1.6% |
| FY2022 | $263.5M | +13.6% |
| FY2021 | $231.8M | +2.8% |
| FY2020 | $225.5M | -18.1% |
| FY2019 | $275.3M | +3.6% |
| FY2018 | $265.7M | +5.5% |
| FY2017 | $251.8M | +69.9% |
| FY2016 | $148.2M | +12.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026